CGEM — Cullinan Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1789972 ·
Last close
$9.27
Market Cap
$602.14M
52W High
$23.19
52W Low
$8.23
ADV30
868,966
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -52,600,000 | -49,388,000 | 322,559,000 | 88,260,000 | 41,275,000 |
| Jun 2026 | 0 | — | -57,254,000 | -53,704,000 | 363,787,000 | 78,640,000 | 42,033,000 |
| Mar 2026 | 0 | — | -53,697,000 | -49,661,000 | 402,984,000 | 75,081,000 | 36,812,000 |
| Dec 2025 | 0 | — | -55,259,000 | -50,713,000 | 448,374,000 | 88,332,000 | 39,644,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-165,455,000
Investing CF
$147,123,000
Financing CF
$3,257,000
CapEx
$-11,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.07
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-740,872,000
Inventory
—
Receivables
—
ST Investments
$201,313,000
EBIT TTM
$-218,810,000
Pretax Income TTM
$-203,466,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,648,000 | -219,879,000 | 448,374,000 | 39,644,000 | 408,730,000 | -175,750,000 |
| Dec 2024 | 0 | -196,919,000 | -167,383,000 | 621,824,000 | 31,496,000 | 590,328,000 | -145,303,000 |
| Dec 2023 | 0 | -190,649,000 | -153,162,000 | 484,182,000 | 30,287,000 | 453,703,000 | -134,275,000 |
| Dec 2022 | 0 | -132,137,000 | 111,214,000 | 561,117,000 | 26,088,000 | 535,029,000 | -126,664,000 |
TTM Snapshot
Revenues TTM
$17,454,000
NetIncome TTM
$-204,688,000
OpCashFlow TTM
—
Assets (Latest)
$363,787,000
Forward EPS
$-2.36
Max Pain — expiry 2027-01-15
max pain strike: $14.00 · spot: $9.01 · call oi: 3,818 · put oi: 538Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | $608.33M | $10.79 | — |
| DBVT | DBV Technologies S.A. | $627.78M | $9.99 | — |
| SRZN | Surrozen, Inc./DE | $571.47M | $29.98 | — |
| SANA | Sana Biotechnology, Inc. | $563.31M | $1.88 | — |
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
News headlines (Yahoo Finance, 1h cache)
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
2026-11-12 21:30 · Yahoo
Cullinan Therapeutics: Q3 Earnings Snapshot
2026-11-10 12:15 · Yahoo
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-10 12:00 · Yahoo
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
2026-11-09 15:00 · Yahoo
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
2026-11-08 15:30 · Yahoo
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
2026-11-04 14:14 · Yahoo
Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In?
2026-10-31 19:12 · Yahoo
Cullinan Therapeutics (CGEM) Stock May Be Fully Priced Following Trial Progress
2026-10-29 15:16 · Yahoo
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
2026-10-29 12:55 · Yahoo
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
2026-10-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.